Aurora Cannabis launches localized European medical hubs with country-specific websites

Aurora rolls out localized European medical hubs

Aurora Cannabis announces from Edmonton on Feb. 3, 2026 that it launches four new localized websites to bolster its presence in key European medical markets. The central hub, auroramedicine.com, links to dedicated country sites for Germany, the UK and Poland, each presented in the native language of its market. The move forms part of a longer-term strategy to provide a locally relevant digital presence that foregrounds Aurora’s scientific and manufacturing credentials.

Localized portals aim to deepen clinician and partner engagement

The new sites are designed to improve engagement with healthcare professionals, commercial partners and prospective employees by placing products, scientific expertise and partnerships front and centre. Aurora updates videos and photography across the platforms to showcase both Canadian-made and local production, stressing quality, compliance and evidence-based processes. The navigation and content architecture aim to streamline access to clinical information, product specifications and contact routes for medical enquiries.

Aurora positions the roll-out as investment in its fastest-growing region and a way to capture emerging opportunities in an evolving medical cannabis market. Andreas Dotterweich, senior vice president for Aurora Europe, frames the sites as demonstrable evidence of ongoing investment that reinforces the company’s leadership and supports growth in regulated medical channels. The refreshed platforms align with Aurora’s broader European communications strategy and provide enhanced resources for practitioners and partners seeking a trusted, locally compliant information source.

Compliance and manufacturing transparency highlighted

Aurora emphasizes traceability, local compliance and quality assurance across the new sites, reflecting regulatory sensitivities in the European medical market. The digital content explicitly links manufacturing practices and product provenance to regulatory engagement and patient access initiatives, supporting recruitment and partnership development at local levels.

Portfolio alignment with a medical-first strategy

The initiative complements Aurora’s global brand evolution and its medical-first focus on higher-margin opportunities across Canada, Europe, Australia and New Zealand. Aurora’s portfolio — including Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty’s and Whistler Cannabis Co — and its controlling interest in Bevo Farms underpin the company’s aim to capitalise on anticipated market expansion, regulatory reforms and growing clinical adoption across Europe.